1. A Serine Protease Inhibitor, Camostat Mesilate, Suppresses Urinary Plasmin Activity and Alleviates Hypertension and Podocyte Injury in Dahl Salt-Sensitive Rats.
- Author
-
Iwata Y, Deng Q, Kakizoe Y, Nakagawa T, Miyasato Y, Nakagawa M, Nishiguchi K, Nagayoshi Y, Narita Y, Izumi Y, Kuwabara T, Adachi M, and Mukoyama M
- Subjects
- Rats, Animals, Serine Proteinase Inhibitors pharmacology, Serine Proteinase Inhibitors therapeutic use, Fibrinolysin, Rats, Inbred Dahl, Sodium Chloride, Dietary pharmacology, Proteinuria pathology, Blood Pressure, Kidney metabolism, Podocytes metabolism, Hypertension, Serpins pharmacology
- Abstract
In proteinuric renal diseases, the serine protease (SP) plasmin activates the epithelial sodium channel (ENaC) by cleaving its γ subunit. We previously demonstrated that a high-salt (HS) diet provoked hypertension and proteinuria in Dahl salt-sensitive (DS) rats, accompanied by γENaC activation, which were attenuated by camostat mesilate (CM), an SP inhibitor. However, the effects of CM on plasmin activity in DS rats remain unclear. In this study, we investigated the effects of CM on plasmin activity, ENaC activation, and podocyte injury in DS rats. The DS rats were divided into the control diet, HS diet (8.0% NaCl), and HS+CM diet (0.1% CM) groups. After weekly blood pressure measurement and 24-h urine collection, the rats were sacrificed at 5 weeks. The HS group exhibited hypertension, massive proteinuria, increased urinary plasmin, and γENaC activation; CM treatment suppressed these changes. CM prevented plasmin(ogen) attachment to podocytes and mitigated podocyte injury by reducing the number of apoptotic glomerular cells, inhibiting protease-activated receptor-1 activation, and suppressing inflammatory and fibrotic cytokine expression. Our findings highlight the detrimental role of urinary plasmin in the pathogenesis of salt-sensitive hypertension and glomerular injury. Targeting plasmin with SP inhibitors, such as CM, may be a promising therapeutic approach for these conditions.
- Published
- 2023
- Full Text
- View/download PDF